Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Flachenecker

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Der Nervenarzt|October 25, 2017
[What is new in symptomatic MS treatment: Part 1-introduction and methodical approach, ataxia and tremor]T Henze, W Feneberg, P Flachenecker, et al.
Der Nervenarzt|October 29, 2017
[What is new in symptomatic MS treatment: Part 3-bladder dysfunction]T Henze, W Feneberg, P Flachenecker, et al.
Der Nervenarzt|October 29, 2017
[New aspects of symptomatic MS treatment: Part 4-sexual dysfunction and eye movement disorders]T Henze, W Feneberg, P Flachenecker, et al.
Transfusion Science|February 6, 1998
Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamideP Flachenecker, B M Taleghani, R Gold, et al.
Der Nervenarzt|October 29, 2017
[New aspects of symptomatic MS treatment: Part 5 - fatigue]T Henze, W Feneberg, P Flachenecker, et al.
Der Nervenarzt|October 29, 2017
[New aspects of symptomatic MS treatment: Part 6 - cognitive dysfunction and rehabilitation]T Henze, W Feneberg, P Flachenecker, et al.
Neurology|September 25, 2003
Fatigue in MS is related to sympathetic vasomotor dysfunctionP Flachenecker, A Rufer, I Bihler, et al.
Acta Neurologica Scandinavica|January 25, 2003
Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approachesV I Leussink, P Flachenecker, D Brechtelsbauer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 12, 2002
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parametersP Flachenecker, T Kümpfel, B Kallmann, et al.
European Journal of Neurology|January 26, 2013
Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosisK Baumstarck, J Pelletier, H Butzkueven, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Der Nervenarzt|October 25, 2017
[What is new in symptomatic MS treatment: Part 1-introduction and methodical approach, ataxia and tremor]T Henze, W Feneberg, P Flachenecker, et al.
Der Nervenarzt|October 29, 2017
[What is new in symptomatic MS treatment: Part 3-bladder dysfunction]T Henze, W Feneberg, P Flachenecker, et al.
Der Nervenarzt|October 29, 2017
[New aspects of symptomatic MS treatment: Part 4-sexual dysfunction and eye movement disorders]T Henze, W Feneberg, P Flachenecker, et al.
Transfusion Science|February 6, 1998
Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamideP Flachenecker, B M Taleghani, R Gold, et al.
Der Nervenarzt|October 29, 2017
[New aspects of symptomatic MS treatment: Part 5 - fatigue]T Henze, W Feneberg, P Flachenecker, et al.
Der Nervenarzt|October 29, 2017
[New aspects of symptomatic MS treatment: Part 6 - cognitive dysfunction and rehabilitation]T Henze, W Feneberg, P Flachenecker, et al.
Neurology|September 25, 2003
Fatigue in MS is related to sympathetic vasomotor dysfunctionP Flachenecker, A Rufer, I Bihler, et al.
Acta Neurologica Scandinavica|January 25, 2003
Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approachesV I Leussink, P Flachenecker, D Brechtelsbauer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 12, 2002
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parametersP Flachenecker, T Kümpfel, B Kallmann, et al.
European Journal of Neurology|January 26, 2013
Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosisK Baumstarck, J Pelletier, H Butzkueven, et al.
Pageof 5